Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism: The PADIS-PE Randomized Clinical Trial

• Published in: JAMA : the journal of the American Medical Association 2015-07, Vol.314 (1), p.31-40
• Main Authors: Couturaud, Francis, Sanchez, Olivier, Pernod, Gilles, Mismetti, Patrick, Jego, Patrick, Duhamel, Elisabeth, Provost, Karine, dit Sollier, Claire Bal, Presles, Emilie, Castellant, Philippe, Parent, Florence, Salaun, Pierre-Yves, Bressollette, Luc, Nonent, Michel, Lorillon, Philippe, Girard, Philippe, Lacut, Karine, Guégan, Marie, Bosson, Jean-Luc, Laporte, Silvy, Leroyer, Christophe, Décousus, Hervé, Meyer, Guy, Mottier, Dominique
• Format: Article
• Language: English
• Subjects: Adult; Aged; Anticoagulants; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Cardiology and cardiovascular system; Clinical trials; Double-Blind Method; Drug Administration Schedule; Drug therapy; Hemorrhage - chemically induced; Human health and pathology; Humans; Life Sciences; Middle Aged; Pulmonary Embolism - drug therapy; Recurrence; Risk Factors; Secondary Prevention; Thrombosis; Venous Thromboembolism - prevention & control; Warfarin - administration & dosage; Warfarin - adverse effects
• ISSN: 0098-7484; 1538-3598
• DOI: 10.1001/jama.2015.7046

IMPORTANCE: The optimal duration of anticoagulation after a first episode of unprovoked pulmonary embolism is uncertain. OBJECTIVES: To determine the benefits and harms of an additional 18-month treatment with warfarin vs placebo, after an initial 6-month nonrandomized treatment period on a vitamin K antagonist. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind trial (treatment period, 18 months; median follow-up, 24 months); 371 adult patients who had experienced a first episode of symptomatic unprovoked pulmonary embolism (ie, with no major risk factor for thrombosis) and had been treated initially for 6 uninterrupted months with a vitamin K antagonist were randomized and followed up between July 2007 and September 2014 in 14 French centers. INTERVENTIONS: Warfarin or placebo for 18 months. MAIN OUTCOMES AND MEASURES: The primary outcome was the composite of recurrent venous thromboembolism or major bleeding at 18 months after randomization. Secondary outcomes were the composite at 42 months (treatment period plus 24-month follow-up), as well as each component of the composite, and death unrelated to pulmonary embolism or major bleeding, at 18 and 42 months. RESULTS: After randomization, 4 patients were lost to follow-up, all after month 18, and 1 withdrew due to an adverse event. During the 18-month treatment period, the primary outcome occurred in 6 of 184 patients (3.3%) in the warfarin group and in 25 of 187 (13.5%) in the placebo group (hazard ratio [HR], 0.22; 95% CI, 0.09-0.55; P = .001). Recurrent venous thromboembolism occurred in 3 patients in the warfarin group and 25 patients in the placebo group (HR, 0.15; 95% CI, 0.05-0.43); major bleeding occurred in 4 patients in the warfarin group and in 1 patient in the placebo group (HR, 3.96; 95% CI, 0.44 to 35.89). During the 42-month entire study period (including the study treatment and follow-up periods), the composite outcome occurred in 33 patients (20.8%) in the warfarin group and in 42 (24.0%) in the placebo group (HR, 0.75; 95% CI, 0.47-1.18). Rates of recurrent venous thromboembolism, major bleeding, and unrelated death did not differ between groups. CONCLUSIONS AND RELEVANCE: Among patients with a first episode of unprovoked pulmonary embolism who received 6 months of anticoagulant treatment, an additional 18 months of treatment with warfarin reduced the composite outcome of recurrent venous thrombosis and major bleeding compared with placebo. However, benefit was not maintained a